Cardiac gene therapy in large animals: bridge from bench to bedside.

Authors:
Address: Cardiovascular Research Center, Mount Sinai School of Medicine, New York, NY, USA.
Journal:


Publication:

abstract

Several clinical trials are evaluating gene transfer as a therapeutic approach to treat Cardiac diseases. Although it has just started on the path to clinical application, recent advances in gene delivery technologies with increasing knowledge of underlying mechanisms raise great expectations for the cardiac gene therapy. Although in vivo experiments using small animals provide the therapeutic potential of gene transfer, there exist many fundamental differences between the small animal and the human hearts. Before applying the therapy to clinical patients, large animal studies are a prerequisite to validate the efficacy in an animal model more relevant to the human heart. Several key factors including vector type, injected dose, delivery method and targeted cardiac disease are all important factors that determine the therapeutic efficacy. Selecting the most optimal combination of these factors is essential for successful gene therapy. In addition to the efficacy, safety profiles need to be addressed as well. In this regard, large animal studies are best suited for comprehensive evaluation at the preclinical stages of therapeutic development to ensure safe and effective gene transfer. As the cardiac gene therapy expands its potential, large animal studies will become more important to bridge the bench side knowledge to the clinical arena.Gene Therapy advance online publication, 2 February 2012; doi:10.1038/gt.2012.3.



Related Articles
Review [Development of antituberculous drugs: current status and future prospects].
Kekkaku. 2006
Review [Development of antituberculous drugs: current status and future prospects].
Tomioka H, Namba K. Kekkaku. 2006 Dec; 81(12):753-74.
Review Stem cells and cardiac repair: a critical analysis.
J Cardiovasc Transl Res. 2008
Review Stem cells and cardiac repair: a critical analysis.
Dinsmore JH, Dib N. J Cardiovasc Transl Res. 2008 Mar; 1(1):41-54. Epub 2008 Jan 31.
Percutaneous methods of vector delivery in preclinical models.
Gene Ther. 2012
Percutaneous methods of vector delivery in preclinical models.
Ladage D, Ishikawa K, Tilemann L, Müller-Ehmsen J, Kawase Y. Gene Ther. 2012 Mar 15; . Epub 2012 Mar 15.
Review The future of human gene therapy.
Mol Aspects Med. 2001
Review The future of human gene therapy.
Rubanyi GM. Mol Aspects Med. 2001 Jun; 22(3):113-42.
Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
Hum Gene Ther. 2001
Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ, Kaplitt MG, Stern MB, Eidelberg D. Hum Gene Ther. 2001 Aug 10; 12(12):1589-91.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.